Introduction
XPO1, one of seven nuclear exportin proteins required for all mammalian cells, shuttles ~220 diverse proteins and some RNAs from the nucleus to the cytoplasm (1) (2) (3) (4) . XPO1 interacts with cargo proteins through a nuclear export sequence (NES) that is dependent on the small GTPase protein Ran in its GTP-bound form, which binds to XPO1 together with export cargos (2) . NES-containing cargo proteins include multiple transcription factors and tumor suppressor proteins that play key roles in the growth and survival of cancer cells. Interestingly, XPO1 is the sole nuclear export protein for the major tumor suppressor proteins [e.g. p53 (5), STAT3 (6), survivin (7), FOXO3 (8) ]. Many of these proteins lose their tumor suppressor function when they are exported out of the nucleus. Therefore, inhibiting XPO1, leading to forced nuclear localization, accumulation and activation of tumor suppressor proteins, is considered a potential therapeutic target for anti-cancer drug development.
Survivin is a multi-functional protein with its major oncogenic property being inhibition of caspase-dependent apoptosis that it accomplishes, in part, by stabilizing XIAP in the cytoplasm of tumor cells (9) . Survivin is highly expressed in breast tumor cells and is one of the genes profiled on OncoDx and Mammoprint as a predictor of clinical response to therapy (10) .
Survivin export from the nucleus to the cytoplasm is mediated by the XPO1-Ran-GTP complex (7, 11) ; cytoplasmic localization is required for survivin's anti-apoptotic and tumor-promoting functions (12) (13) (14) . Disruption of the survivin NES leads to enhanced susceptibility to anti-cancer treatments (12, 14) . One mechanism of targeting survivin's selective cytoplasmic function without affecting its anti-tumor nuclear effects could be to inhibit its cytoplasmic export.
STAT3 is a member of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) that is constitutively activated in multiple cancer types (15) , including triple-negative breast cancer (TNBC). STAT3 activation in these tumors leads to increased expression of anti-apoptotic proteins, including survivin (16, 17) , and other proteins to enhance cell proliferation, induce angiogenesis, and suppress immune responses. Thus, STAT3 is a potential high-yield target for drug development to treat TNBC for which there are no currently approved molecular therapies. Although several small-molecule STAT3 inhibitors have been reported (18) (19) (20) , thus far none are in clinical trials due to pharmacokinetic and other problems.
Interestingly, STAT3 has at several NES elements through which it binds to XPO1 for its nuclear export (21) .
Leptomycin B (LMB) was the first natural XPO1 inhibitor discovered that was shown to be a potent anti-cancer agent (22) . This agent failed in an early clinical trials due to off-target side effects predictable from animal toxicity testing, prompting the development of more selective and less toxic XPO1 inhibitors (23) . The recent crystal structure of LMB and XPO1
shows that LMB binds covalently to Cys-528 in the XPO1 NES-binding groove, occupying the majority of the groove and undergoing hydrolysis by XPO1 (24) . Newer small-molecule,
Selective Inhibitors of Nuclear Export (SINE) XPO1 antagonists developed by Karyopharm
Therapeutics bind similarly in the NES groove, however due to their smaller size, these molecules occupy less space and are more specific for XPO1, with no detectable binding to other proteins (24) . X-ray crystal structures of SINEs bound to XPO1 have been published and confirm covalent modification of Cys528 (24) tumors (25, 26) . The exact molecular mechanism of their anti-tumor effects in different cancer subtypes is not yet well-defined.
We sought to characterize the effects of XPO1 inhibition on survivin using a breast cancer model and the SINE compounds. In vitro and in vivo assays demonstrated that these drugs potently inhibit breast cancer growth by blocking proliferation and enhancing cell death pathways, as demonstrated for other tumor types. Importantly, here we show that these compounds can dramatically repress Survivin transcription by blocking STAT3 transactivation and that they enhance survivin degradation through cleavage by caspase-3. These results identify survivin-and STAT3-dependent mechanisms for the XPO1 inhibitors that may explain their in vivo anti-tumor effects. We also note that XPO1 inhibitors force the nuclear retention of tumor suppressor proteins p53, FOXO and others (25) . Together, these data show that XPO1 inhibition confers very different effects on oncogenic drivers (i.e., cytoplasmic survivin, survivin degradation) compared with growth regulatory proteins (i.e., nuclear p53, growth suppressive nuclear survivin). These findings suggest that nuclear export could represent an important switch between oncogenesis and tumor suppression.
Materials and Methods

Cell lines and reagents
All tumor cell lines were purchased from and tested by the American Type Culture Collection. Cell lines were passaged less than six months for these studies. XPO1 inhibitors (KPT-185cis, KPT-185trans, KPT-276, KPT-330) were obtained from Karyopharm Therapeutics, Inc. A 10mM stock solution dissolved in DMSO was diluted in medium to the final concentrations indicated. To inhibit protein translation, cells were treated with 20μg/ml cyclohexamide (Sigma-Aldrich). To inhibit proteasome-mediated degradation, cells were treated with 2μM MG132 (SelleckBio.com) for 18h or 40μM MG132 for 6h. To inhibit caspase-3 and caspase-9, cells were treated with 20 μM of inhibitors for 4 hours. 6× MYC-survivin was a gift from H. Cheung. Cells were transfected with siRNA to XPO1 (Ambion/Invitrogen), survivin (Cell Signaling), XIAP (Thermo Scientific Dharmacon) or control (Thermo Scientific Dharmacon).
Cell viability and apoptosis assays
Cells were seeded at a density of 5000 cells/well then treated at the doses indicated. 72 hours later, cells were incubated with CellTiter 96 Aqueous One Solution Reagent (Promega), and viability was assessed using a Synergy Mx Monochromator (BioTek Instrument Inc.). Flow cytometry-based apoptosis assays were performed with the Annexin V-FITC Apoptosis Kit 
Subcellular fractionation, immunoprecipitation, western blot, and tricine-SDS-PAGE
Subcellular fractionation was performed as previously described (27) . Immunocomplexes were resolved by SDS-PAGE. Tricine-SDS-PAGE was carried out as described (28) 
Immunohistochemistry and TUNEL
Immunohistochemistry (IHC) was performed as described (13) . Tumor sections were deparaffinized and antigen retrieval was performed prior to primary antibody incubation. 
Quantitative RT-PCR
PCR (qRT-PCR) for Survivin and Gapdh was performed as described (13) . Results were analyzed using the ABI HT7900 Sequence Detection System. Relative quantification was performed using the standard curve method. 
Results
Inhibition of XPO1 inhibits tumor cell growth and enhances apoptosis in breast cancer cells
The panel of SINE reagents used here (KPT-185cis, KPT-185trans, KPT-251, KPT-276, KPT-330) are similar drug-like small molecules that share a trifluoromethyl phenyl triazole scaffold ( Supplementary Fig. S1 ) (24) . KPT-185trans, the trans isomer of KPT-185cis, has been reported to elicit 10-50 fold reduced XPO1 inhibition and apoptosis induction and serves as a negative control (29) . To determine the effects of these XPO1 inhibitors on the growth of breast (Fig. 1A) . The IC50 for each compound was then calculated ( Table 1 ). The KPT-330 compound (currently in Phase 1 clinical trials) was the most potent growth inhibitor in these cell lines, with IC50 values of 5-21 nM, while the KPT-185trans drug had significantly higher IC50 values (893-6200 nM), consistent with its altered structure that inhibits binding to the XPO1 NES site, and with the dependence of growth inhibition on XPO1 antagonism (29) . To determine the time course of growth inhibition, we performed cell viability assays at 0, 24, 48, and 72 hours after treatment using 1μM of each agent. KPT-185cis, KPT-251, and KPT-276 markedly reduced cell viability in all three breast cancer cells evaluated, while the KPT-185trans compound had minimal effects on viability in MCF7 and MDA-MB-231 cells (Fig.1B) .
To determine the effects of the SINE compounds on apoptosis, we treated SKBR3 and MDA-MB-486 cells with varying doses of KPT-276 and KPT-330 for 24 hours. Cells treated with 10 μM KPT-276 showed a 5-fold increase in apoptosis over untreated control cells and a 2-fold increase in apoptosis over cells treated with the pro-apoptotic drug staurosporine (Fig. 1C ).
This indicates that these compounds can induce apoptosis at higher doses than required to just inhibit cell growth. To determine whether apoptosis was induced in a caspase-dependent manner, we treated SKBR3 and MDA-MB-468 cells with varying doses of KPT-276 and KPT-330 for 24 hours then performed western blots for caspase-3, cleaved caspase-3, PARP and cleaved PARP.
KPT-276 induced PARP and caspase-3 cleavage at doses greater than 1 μM (Fig. 1D ), while KPT-330 induced PARP and caspase-3 cleavage at doses greater than 0.01 μM, indicating that apoptosis is mediated at least in part by caspase-3-dependent mechanisms and that KPT-330 is more potent at inducing apoptosis.
XPO1 inhibition retards breast tumor growth in vivo
To determine the effects of XPO1 inhibition on TNBC growth in vivo, we used MDA-MB-468 cells to create human xenograft tumors in SCID mice. Once tumors were established To determine whether the tumor cells showed evidence of changes in proliferation and/or apoptosis after treatment in vivo, we dissected tumors from animals after 42 days of treatment and stained sections with the proliferation marker, Ki67 and the marker for apoptosis, TUNEL.
Results showed a decrease in the number of Ki67-positive cells remaining after treatment with KPT-330, and an increase in TUNEL-positive cells in the remaining tumor tissue (Fig. 2C) . To correlate the drug levels achieved in vivo with our in vitro experiments, we performed limited pharmacokinetic studies, measuring plasma concentration of KPT-330 over the first 24 hours after IV and po drug administration ( Supplementary Fig. S2 ). The serum concentration of KPT-330 was ~1000ng/ml 4 hours after treatment. This is approximately the same concentration achieved in vitro at the measured apoptotic time point of 24 hours (Fig. 1C) therefore they are relatively similar in concentration. Together, these data show that KPT-330 reduces proliferation and induces apoptosis in breast tumor cells.
Nuclear retention of survivin promotes survivin loss
In previous work, we determined that survivin acetylation at Lys-129 enhances its stability as a homodimer within the nucleus of breast cancer cells where it interacts with the chromosomal passenger complex during mitosis (13) . We also showed that survivin deacetylation by HDAC6 facilitates monomeric survivin to bind XPO1 for nuclear export which is required for its anti-apoptotic function (27) . We hypothesized that inhibition of XPO1 by the SINE compounds, as with the natural product XPO1 inhibitor LMB (13), would block survivin nuclear export. To determine the effects of XPO1-inhibition by these compounds on survivin nuclear export, we treated 2 different breast tumor cell lines (MCF7 and SKBR3) with or without 10 μM KPT-276 and prepared nuclear and cytosolic protein fractions. Cells were lysed and proteins analyzed by western blot. A decrease in cytosolic survivin protein was observed as early as 4 hours and an increase in nuclear protein by 4 hours after treatment ( Fig. 3A and 3B ).
Survivin continued to accumulate within the nucleus until 12 hours after treatment, after which time it decreased dramatically both within this compartment and within the cytosol. These results suggest that XPO1 inhibition initially promotes survivin nuclear localization, but at later time points leads to a reduction in total survivin protein levels in vitro. This decrease in survivin protein levels correlates with the timing of the cellular anti-tumor effects of these compounds and supports a hypothesis that XPO1 inhibition leads to a loss of survivin protein which then leads to inhibition of tumor cell growth and enhanced tumor cell apoptosis.
To validate whether the decrease in survivin protein after KPT treatment is specific to its inhibition of XPO1, we treated MCF7 and SKBR3 cells with two different XPO1 siRNAs and measured survivin protein by western blot. XPO1 knockdown decreased survivin protein levels, similar to that observed with SINE treatment alone (Fig. 3C) (Fig. 3D) , suggesting that loss of survivin-XPO1 binding is not required for the observed effects on the decrease in survivin protein levels.
To determine the contribution of the loss of survivin to apoptosis following XPO1 inhibition, we used siRNA to knockdown Survivin in SKBR3 cells then treated these cells with or without 5 μM KPT-276. Survivin knockdown resulted in a two-fold increase in apoptosis over control siRNA-treated cells, as measured by Annexin V FACS (Fig. 4A) , suggesting either a synergistic or additive effect of survivin loss on cell death. To determine whether the SINE compounds antagonize the survivin-mediated anti-apoptosis pathway, we performed experiments to assess whether survivin could rescue SKBR3 cells from SINE-mediated apoptosis. To this end, we overexpressed a MYC-tagged survivin expression construct in SKBR3 cells then treated the cells with or without 5 μM KPT-276. Exogenous expression of survivin protected SINEtreated cells from apoptosis, as measured by Annexin V FACs (Fig. 4B) . Together, these results suggest that survivin plays a functional role in the apoptosis pathway, as stimulated by XPO1 inhibition in breast cancer cells.
XPO1 inhibition promotes survivin degradation through caspase 3 activation
To further characterize the observed effects on survivin protein loss after nuclear retention, we performed a dose-response and time course of survivin protein expression with KPT-276 in SKBR3 cells. Results showed that survivin protein decreased after 12 hours and was undetectable by 72 hours after treatment (Fig. 5A) . Doses of 100nM of drug led to a 10-fold decrease in survivin protein, while 10 μM of drug resulted in near disappearance of the protein (Fig. 5B) . To determine whether the observed decrease in protein levels could occur as a result of 
changes in protein stability, we examined survivin protein levels after inhibiting protein synthesis in the presence and absence of the drug. SKBR3 cells were treated with the protein synthesis inhibitor cyclohexamide (CHX) then with or without 5 μM of KPT-276. Results showed that survivin protein levels decreased further after treatment with KPT-276, indicating that inhibition of XPO1 and survivin nuclear export accelerates survivin protein degradation (Fig. 5C ).
Survivin is known to be degraded by the ubiquitin/proteasomal degradation pathway which is stimulated when tumor cells are arrested in the G1 phase of the cell cycle (30).
Therefore we examined whether XPO1 inhibition could stimulate this pathway. To this end, we blocked ubiquitin-mediated proteasome degradation by treating SKBR3 cells with the 26S-proteosome inhibitor, MG132. MG132 had an effect on protecting cells from KPT-mediated survivin degradation, shown as a small increase in survivin protein levels at 12 and 24 hours after treatment with both MG132 and KPT-276 compared with KPT-276 alone ( Fig. 5D and Supplementary Fig. S3A ). The X-linked inhibitor of apoptosis (XIAP) contains a RING domain possessing E3 ligase activity that participates in the ubiquitin-proteasome pathway (31) and has been demonstrated to be one of the mechanisms of ubiquitin-proteasomal degradation of survivin (32) . To examine whether XIAP was required for ubiquitin-proteasomal degradation of survivin in response to its nuclear retention, we treated SKBR3 cells with XIAP siRNA then examined survivin levels after XPO1 inhibition. Downregulation of XIAP did not restore survivin levels after KPT treatment ( Supplementary Fig. S4 ), suggesting that other proteins are likely involved in regulating survivin degradation in the nuclear compartment.
To investigate the potential requirements for survivin degradation in response to KPT drugs, we used the pan-caspase inhibitor Z-VAD to block the penultimate proteolytic pathway. Treatment of SKBR3 cells with Z-VAD in the presence of KPT-276 inhibited survivin degradation (Fig. 5E ), suggesting that caspase proteins are required for this process. To uncover the specific caspase protein(s) responsible for this phenotype, we used inhibitors to the caspase 3 and caspase 9 proteins. Treatment with either inhibitor significantly blocked survivin degradation by KPT-276 ( Fig. 5F and Supplementary Fig. S3B ), supporting a role for these proteases in survivin cleavage after XPO1 inhibition. To determine whether caspase-mediated survivin degradation was dependent on XPO1, we depleted MCF7 cells of XPO1 using XPO1 siRNA in the presence and absence of Z-VAD. Inhibition of caspase activity with Z-VAD partially restored survivin levels from XPO1 siRNA-treated cells (Fig. 5G) , supporting that XPO1 blocks caspase-mediated survivin degradation. To further examine survivin cleavage by caspase 3 we used a cell-free system. Whole cell lysates were treated with recombinant active caspase 3 protein over a time course at 37 C. After 2 hours, we detected a large amount of cleaved survivin protein (Fig. 5H) . Together, these data support a role for caspase-3 in cleaving survivin in response to SINE-mediated survivin nuclear retention.
XPO1 inhibition represses Survivin transcription by inhibiting STAT3 transactivation
To gain further insight into a mechanism whereby XPO1 inhibition and survivin nuclear retention results in loss of survivin, we determined the dose and time-dependent effects of the SINE drugs on Survivin mRNA. We treated SKBR3 cells with 5μM KPT-276 over a time course Signal transducer and activator of transcription 3 (STAT3) is a latent cytosolic transcription factor that stimulates Survivin transcription in the nucleus in response to growth factors and cytokines such as epidermal growth factor (EGF) and interleukin-6 (IL-6)(15). For its activation, it requires either phosphorylation by the Janus kinase proteins or acetylation by CREB-BindingProtein (CBP) (33) . In prior work, we showed that nuclear survivin binds the transactivation domain of STAT3 and inhibits STAT3 enhancesome activity (13) .
To establish a potential effect of the SINE compounds on STAT3 transactivation, we co- (Fig. 6C) . Together, these results suggest that KPT-276 can block the ability of STAT3 to transcriptionally activate some of its target genes.
To determine whether KPT-276 directly affects endogenous STAT3 protein levels, we treated SKBR3 cells with or without KPT-276 and examined endogenous STAT3 levels. lower magnitude than that observed for the effect on survivin protein levels (Fig. 6D) (Fig. 6F and 6G ). These data confirm that KPT inhibition of XPO1 regulates Survivin transcription through inhibition of STAT3 transactivation.
To examine the in vivo effects of the SINES on survivin and STAT3 we immunostained tumor tissue isolated from mice that had been treated with KPT-330 for 42 days (Fig. 6H) 
Discussion
Inhibition of nucleo-cytoplasmic transport by natural and synthetic products has been pursued as a therapeutic avenue in cancer based on a number of biological observations (34) .
Multiple tumor suppressor proteins, as well as XPO1 itself, are mislocalized or expressed at supraphysiologic levels within cancer cells (35, 36) . Empiric evidence also shows that derivatized natural product or drug-like small molecule SINE XPO1 inhibitors (29) are highly efficacious at functioning as anti-cancer agents in several in vitro and in vivo models of human cancer. The focus of many recent studies of these inhibitors, including the SINES, has been to demonstrate efficacy in different tumor types and to define the pharmacokinetic profiles of these different drugs. Additionally, detailed in vitro binding and protein structural studies have shown that the SINES have exquisite specificity for the XPO1-NES binding groove and that unlike other XPO1 inhibitors they do not bind cysteine proteases, thus limiting their off-target effects (24, 25) . Although many of these drugs have been demonstrated to inhibit tumor cell growth and have some effects at enhancing programmed cell death in cancer cells, the signaling pathways by which they convey these effects have not been extensively explored.
Breast cancer is the most common cancer in women and carries a 15% mortality rate (37) . Improvements in personalized medicine with molecular characterization of breast tumor subtypes and the availability of biological agents have enhanced survival rates for many patients with the exception of triple negative (ER-, PR-, Her2-) and basal breast tumors for which biological therapies are not yet available. Very high levels of survivin expression are independent risk factors for poor prognosis in several clinical breast cancer studies (38, 39) .
Cytoplasmic survivin has been shown to be particularly high in breast tumors and to be an independent predictor of poor prognosis (40), while nuclear survivin has been a favorable factor As reported in our study, KPT-276 represses STAT3 transactivation to inhibit Survivin transcription as a major mechanism by which it acts to deplete total survivin protein levels. transcription factors, kinases, enzymes involved in DNA repair, and cytoskeletal proteins. In addition, several proteins essential for cell cycle regulation, such as pRb (48) , MDM2 (49), p21WAF1/CIP1, p27Kip1 (50) , and STAT3 (51) are also caspase targets. Prior to our study, survivin was not a known caspase target. An algorithm for prediction of caspase substrate cleavage sites identifies 5 potential caspase cleavage sites in the human survivin protein (52, 53) .
One such site, at the N-terminal region of the human survivin protein (FLKD, position [13] [14] [15] [16] [17] [18] would be consistent with the observed cleavage pattern identified here (Fig. 5H) . These results add to the repertoire of caspase-substrates and provide a biochemical mechanism for the critical role for survivin in the function of the SINE XPO1 antagonists. Together, this study expands the application of these agents in the treatment of breast cancer and other tumors. 
